Potential Immunologic Targets for Treating Fibrosis in Systemic Sclerosis: A Review Focused on Leukocytes and Cytokines

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 3, 2012, Pages 281-296

  Hasegawa, Minoru ^a   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Cytokine; Fibrosis; Leukocyte; Pathogenesis; Sclerosis; Systemic; Treatment

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ABATACEPT; ALPHA INTERFERON; AMBRISENTAN; BELIMUMAB; BOSENTAN; CD19 ANTIGEN; CD20 ANTIGEN; CYTOKINE; EPRATUZUMAB; ETANERCEPT; GAMMA INTERFERON; IMATINIB; INFLIXIMAB; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 17 ANTIBODY; LATENCY ASSOCIATED PEPTIDE; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GAMMA INTERFERON; RITUXIMAB; SB 525334; SIS 3; SITAXSENTAN; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; FIBROBLAST; FIBROSIS; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; INTERSTITIAL LUNG DISEASE; LEUKOCYTE; LUNG FIBROSIS; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS VULGARIS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CYTOKINES; DRUG DELIVERY SYSTEMS; FIBROSIS; HUMANS; INTERLEUKINS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84869098469     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.03.014     Document Type: Article

References (189)

1. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35(1):35-42.
2. Simms R.W., Korn J.H. Cytokine directed therapy in scleroderma: Rationale, current status, and the future. Curr Opin Rheumatol 2002, 14(6):717-722.
3. Denton C.P., Black C.M. Targeted therapy comes of age in scleroderma. Trends Immunol 2005, 26(11):596-602.
4. Charles C., Clements P., Furst D.E. Systemic sclerosis: Hypothesis-driven treatment strategies. Lancet 2006, 367(9523):1683-1691.
5. Varga J., Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117(3):557-567.
6. Ramos-Casals M., Fonollosa-Pla V., Brito-Zerón P., Sisó-Almirall A. Targeted therapy for systemic sclerosis: How close are we?. Nat Rev Rheumatol 2010, 6(5):269-278.
7. Ong V.H., Denton C.P. Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 2010, 22(3):264-272.
8. Tyndall A., Koike T. High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction. Intern Med 2002, 41(8):608-612.
9. Vonk M.C., Marjanovic Z., van den Hoogen F.H., Zohar S., Schattenberg A.V., Fibbe W.E., et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008, 67(1):98-104.
10. Burt R.K., Shah S.J., Dill K., Grant T., Gheorghiade M., Schroeder J., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial. Lancet 2011, 378(9790):498-506.
11. Gu Y.S., Kong J., Cheema G.S., Keen C.L., Wick G., Gershwin M.E. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008, 38(2):132-160.
12. Waldburger J.M., Firestein G.S. Garden of therapeutic delights: New targets in rheumatic diseases. Arthritis Res Ther 2009, 11(1):206.
13. Bournia V.K., Vlachoyiannopoulos P.G., Selmi C., Moutsopoulos H.M., Gershwin M.E. Recent advances in the treatment of systemic sclerosis. Clin Rev Allergy Immunol 2009, 36(2-3):176-200.
14. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2009 2010, 69(Suppl 1):i2-i29.
15. Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010, 37(1):54-70.
16. Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010, 37(1):11-25.
17. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Korfiatis P., et al. Is there a role for B-cell depletion as therapy for scleroderma?. A case report and review of the literature. Semin Arthritis Rheum 2010, 40(2):127-136.
18. Baraut J., Michel L., Verrecchia F., Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010, 10(2):65-73.
19. Wick G., Backovic A., Rabensteiner E., Plank N., Schwentner C., Sgonc R. The immunology of fibrosis: Innate and adaptive responses. Trends Immunol 2010, 31(3):110-119.
20. Phumethum V., Jamal S., Johnson S.R. Biologic therapy for systemic sclerosis: A systematic review. J Rheumatol 2011, 38(2):289-296.
21. van Bon L., Cossu M., Radstake T.R. An update on an immune system that goes awry in systemic sclerosis. Curr Opin Rheumatol 2011, 23(6):505-510.
22. Bhattacharyya S., Wei J., Varga J. Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012, 8(1):42-54.
23. Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009, 21(6):623-629.
24. Abraham D.J., Varga J. Scleroderma: From cell and molecular mechanisms to disease models. Trends Immunol 2005, 26(11):587-595.
25. Gardner H., Shearstone J.R., Bandaru R., Crowell T., Lynes M., Trojanowska M., et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006, 54(6):1961-1973.
26. Lemaire R., Farina G., Bayle J., Dimarzio M., Pendergrass S.A., Milano A., et al. Antagonistic effect of the matricellular signaling protein CCN3 on TGF-beta- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome. J Invest Dermatol 2010, 130(6):1514-1523.
27. Wei J., Melichian D., Komura K., Hinchcliff M., Lam A.P., Lafyatis R., et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?. Arthritis Rheum 2011, 63(6):1707-1717.
28. Bergmann C., Akhmetshina A., Dees C., Palumbo K., Zerr P., Beyer C., et al. Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011, 70(12):2191-2198.
29. Dees C., Tomcik M., Zerr P., Akhmetshina A., Horn A., Palumbo K., et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011, 70(7):1304-1310.
30. Wei J., Ghosh A.K., Sargent J.L., Komura K., Wu M., Huang Q.Q., et al. PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: A novel mechanism for progressive fibrogenesis. PLoS ONE 2010, 5(11):e13778.
31. Kalogerou A., Gelou E., Mountantonakis S., Settas L., Zafiriou E., Sakkas L. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005, 64(8):1233-1235.
32. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4(8):583-594.
33. Aliprantis A.O., Wang J., Fathman J.W., Lemaire R., Dorfman D.M., Lafyatis R., et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007, 104(8):2827-2830.
34. Boin F., De Fanis U., Bartlett S.J., Wigley F.M., Rosen A., Casolaro V. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008, 58(4):1165-1174.
35. Sakkas L.I., Platsoucas C.D. Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum 2004, 50(6):1721-1733.
36. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43(11):2455-2463.
37. Murata M., Fujimoto M., Matsushita T., Hamaguchi Y., Hasegawa M., Takehara K., et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?. J Dermatol Sci 2008, 50(3):240-242.
38. Radstake T.R., van Bon L., Broen J., Hussiani A., Hesselstrand R., Wuttge D.M., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS ONE 2009, 4(6):e5903.
39. Fenoglio D., Battaglia F., Parodi A., Stringara S., Negrini S., Panico N., et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011, 139(3):249-257.
40. Gourh P., Arnett F.C., Assassi S., Tan F.K., Huang M., Diekman L., et al. Plasma cytokine profiles in systemic sclerosis: Associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009, 11(5):R147.
41. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W., et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010, 207(3):535-552.
42. De Palma R., D'Aiuto E., Vettori S., Cuoppolo P., Abbate G., Valentini G. Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: Is T-cell response aimed to play a protective role?. Rheumatol Oxf Engl 2010, 49(7):1257-1266.
43. Antiga E., Quaglino P., Bellandi S., Volpi W., Del Bianco E., Comessatti A., et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010, 162(5):1056-1063.
44. Klein S., Kretz C.C., Ruland V., Stumpf C., Haust M., Hartschuh W., et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 2011, 70(8):1475-1481.
45. Radstake T.R., van Bon L., Broen J., Wenink M., Santegoets K., Deng Y., et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS ONE 2009, 4(6):e5981.
46. Slobodin G., Ahmad M.S., Rosner I., Peri R., Rozenbaum M., Kessel A., et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010, 261(2):77-80.
47. Giovannetti A., Rosato E., Renzi C., Maselli A., Gambardella L., Giammarioli A.M., et al. Analyses of T cell phenotype and function reveal an altered T cell homeostasis in systemic sclerosis. Correlations with disease severity and phenotypes. Clin Immunol 2010, 137(1):122-133.
48. Voo K.S., Wang Y.H., Santori F.R., Boggiano C., Wang Y.H., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 2009, 106(12):4793-4798.
49. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci U S A 2009, 106(21):8635-8640.
50. Beriou G., Costantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009, 113(18):4240-4249.
51. + ICOS+ Foxp3+ T cells contribute to overproduction of IL-10 and are correlated with disease severity in patients with systemic lupus erythematosus. Lupus 2011, 20(6):620-627.
52. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54(9):2807-2816.
53. Tanaka C., Fujimoto M., Hamaguchi Y., Sato S., Takehara K., Hasegawa M. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway. Arthritis Rheum 2010, 62(6):1723-1732.
54. Komura K., Fujimoto M., Yanaba K., Matsushita T., Matsushita Y., Horikawa M., et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008, 67(6):867-872.
55. Kawai M., Masuda A., Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 2008, 58(11):3562-3573.
56. Whitfield M.L., Finlay D.R., Murray J.I., Troyanskaya O.G., Chi J.T., Pergamenschikov A., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100(21):12319-12324.
57. Lafyatis R., O'Hara C., Feghali-Bostwick C.A., Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007, 56(9):3167-3168.
58. Lipsky P.E. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2(9):764-766.
59. Sato S., Fujimoto M., Hasegawa M., Takehara K., Tedder T.F. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004, 41(12):1123-1133.
60. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.D., Uchida J., Fujimoto M., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006, 169(3):954-966.
61. Lafyatis R., Kissin E., York M., Farina G., Viger K., Fritzler M.J., et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009, 60(2):578-583.
62. Smith V.P., Van Praet J.T., Vandooren B.R., Vander Cruyssen B., Naeyaert J.M., Decuman S., et al. Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study. Ann Rheum Dis 2010, 69(1):193-197.
63. Daoussis D., Liossis S.N., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study. Rheumatol Oxf Engl 2010, 49(2):271-280.
64. Bosello S., De Santis M., Lama G., Spanò C., Angelucci C., Tolusso B., et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010, 12(2):R54.
65. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54(1):192-201.
66. Navarra S.V., Guzmán R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9767):721-731.
67. Tedder T.F., Inaoki M., Sato S. The CD19/CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997, 6:107-118.
68. Fearon D.T., Carter R.H. The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity. Annu Rev Immunol 1995, 13:127-149.
69. Sato S., Hasegawa M., Fujimoto M., Tedder T.F., Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165(11):6635-6643.
70. Tsuchiya N., Kuroki K., Fujimoto M., Murakami Y., Tedder T.F., Tokunaga K., et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004, 50(12):4002-4007.
71. Sato S., Fujimoto M., Hasegawa M., Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004, 50(6):1918-1927.
72. Hitomi Y., Tsuchiya N., Hasegawa M., Fujimoto M., Takehara K., Tokunaga K., et al. Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis. Tissue Antigens 2007, 69(3):242-249.
73. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109(11):1453-1462.
74. Yoshizaki A., Iwata Y., Komura K., Ogawa F., Hara T., Muroi E., et al. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172(6):1650-1663.
75. Komura K., Yanaba K., Horikawa M., Ogawa F., Fujimoto M., Tedder T.F., et al. CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 2008, 58(11):3574-3584.
76. Asano N., Fujimoto M., Yazawa N., Shirasawa S., Hasegawa M., Okochi H., et al. B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004, 165(2):641-650.
77. York M.R., Nagai T., Mangini A.J., Lemaire R., van Seventer J.M., Lafyatis R. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum 2007, 56(3):1010-1020.
78. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35.
79. Higashi-Kuwata N., Jinnin M., Makino T., Fukushima S., Inoue Y., Muchemwa F.C., et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010, 12(4):R128.
80. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 2005, 118(16):3573-3584.
81. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Anti-TGF beta 1 therapy for diffuse cutaneous systemic sclerosis: A multicenter, randomized, placebo-controlled Phase I/II trial of cat-192. Arthritis Rheum 2004, 50:S691-S692.
82. Santiago B., Gutierrez-Cañas I., Dotor J., Palao G., Lasarte J.J., Ruiz J., et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005, 125(3):450-455.
83. Campioni D., Lo Monaco A., Lanza F., Moretti S., Ferrari L., Fotinidi M., et al. CXCR4 pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. Haematologica 2008, 93(8):1233-1237.
84. Higashiyama H., Yoshimoto D., Kaise T., Matsubara S., Fujiwara M., Kikkawa H., et al. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp Mol Pathol 2007, 83(1):39-46.
85. Jinnin M., Ihn H., Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006, 69(2):597-607.
86. Fang F., Ooka K., Bhattacharyya S., Wei J., Wu M., Du P., et al. The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-beta that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol 2011, 178(5):2077-2090.
87. Frazier K., Williams S., Kothapalli D., Klapper H., Grotendorst G.R. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996, 107:404-411.
88. Abraham D. Connective tissue growth factor: Growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?. Rheumatol Oxf Engl 2008, 47(Suppl 5):v8-v9.
89. Denton C.P., Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: Key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001, 13(6):505-511.
90. Takehara K. Hypothesis: Pathogenesis of systemic sclerosis. J Rheumatol 2003, 30(4):755-759.
91. Ponticos M., Holmes A.M., Shi-wen X., Leoni P., Khan K., Rajkumar V.S., et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 2009, 60(7):2142-2155.
92. Liu S., Shi-wen X., Abraham D.J., Leask A. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum 2011, 63(1):239-246.
93. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15(4):255-273.
94. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354(25):2667-2676.
95. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., Lauwerys B.R., Wikström G., et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009, 60(4):1137-1144.
96. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114(9):1308-1316.
97. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005, 171(11):1279-1285.
98. Distler J.H., Jüngel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56(1):311-322.
99. Akhmetshina A., Venalis P., Dees C., Busch N., Zwerina J., Schett G., et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009, 60(1):219-224.
100. Pope J., McBain D., Petrlich L., Watson S., Vanderhoek L., de Leon F., et al. Imatinib in active diffuse systemic sclerosis: A single site trial. Arthritis Rheum 2011, 63(11):3547-3551.
101. Khanna D., Saggar R., Mayes M.D., Abtin F., Clements P.J., Maranian P., et al. A one year space, phase I / IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011, 63(11):3540-3546.
102. Spiera R.F., Gordon J.K., Mersten J.N., Magro C.M., Mehta M., Wildman H.F., et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011, 70(6):1003-1009.
103. Pope J., McBain D., Petrlich L., Watson S., Vanderhoek L., de Leon F., et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011, 63(11):3547-3551.
104. Avouac J., Fürnrohr B.G., Tomcik M., Palumbo K., Zerr P., Horn A., et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011, 63(3):800-809.
105. Tan F.K., Zhou X., Mayes M.D., Gourh P., Guo X., Marcum C., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatol Oxf Engl 2006, 45(6):694-702.
106. Duan H., Fleming J., Pritchard D.K., Amon L.M., Xue J., Arnett H.A., et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008, 58(5):1465-1474.
107. Kim D., Peck A., Santer D., Patole P., Schwartz S.M., Molitor J.A., et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: Association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008, 58(7):2163-2173.
108. Agarwal S.K., Wu M., Livingston C.K., Parks D.H., Mayes M.D., Arnett F.C., et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 2011, 13(1):R3.
109. Black C.M., Silman A.J., Herrick A.I., Denton C.P., Wilson H., Newman J., et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999, 42(2):299-305.
110. Jimenez S.A., Freundlich B., Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984, 74(3):1112-1116.
111. Ghosh A.K., Yuan W., Mori Y., Chen Sj S., Varga J. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001, 276(14):11041-11048.
112. Granstein R.D., Murphy G.F., Margolis R.J., Byrne M.H., Amento E.P. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 1987, 79(4):1254-1258.
113. Yamamoto T., Takagawa S., Kuroda M., Nishioka K. Effect of interferon-gamma on experimental scleroderma induced by bleomycin. Arch Dermatol Res 2000, 292(7):362-365.
114. Freundlich B., Jimenez S.A., Steen V.D., Medsger T.A., Szkolnicki M., Jaffe H.S. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. Arthritis Rheum 1992, 35(10):1134-1142.
115. Polisson R.P., Gilkeson G.S., Pyun E.H., Pisetsky D.S., Smith E.A., Simon L.S. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: Effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996, 23(4):654-658.
116. Hunzelmann N., Anders S., Fierlbeck G., Hein R., Herrmann K., Albrecht M., et al. Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 1997, 133(5):609-613.
117. Distler J.H., Jordan S., Airo P., Alegre-Sancho J.J., Allanore Y., Balbir Gurman A., et al. Is there a role for TNFα antagonists in the treatment of SSc?. EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 2011, 29(2 Suppl 65):S40-S45.
118. Hu B., Wang S., Zhang Y., Feghali C.A., Dingman J.R., Wright T.M. A nuclear target for interleukin-1alpha: Interaction with the growth suppressor necdin modulates proliferation and collagen expression. Proc Natl Acad Sci U S A 2003, 100(17):10008-10013.
119. Kawaguchi Y., Hara M., Wright T.M. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999, 103(9):1253-1260.
120. Gasse P., Mary C., Guenon I., Noulin N., Charron S., Schnyder-Candrian S., et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007, 117(12):3786-3799.
121. + T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005, 58(2):178-184.
122. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35(1):67-72.
123. + double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007, 56(10):3459-3467.
124. + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42(6):1168-1178.
125. Kodera T., McGaha T.L., Phelps R., Paul W.E., Bona C.A. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci U S A 2002, 99(6):3800-3805.
126. Ong C., Wong C., Roberts C.R., Teh H.S., Jirik F.R. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998, 28(9):2619-2629.
127. King C., Davies J., Mueller R., Lee M.S., Krahl T., Yeung B., et al. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998, 8(5):601-613.
128. Igarashi A., Okochi H., Bradham D.M., Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993, 4:637-645.
129. Rishikof D.C., Ricupero D.A., Kuang P.P., Liu H., Goldstein R.H. Interleukin-4 regulates connective tissue growth factor expression in human lung fibroblasts. J Cell Biochem 2002, 85(3):496-504.
130. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24(2):328-332.
131. + T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009, 60(4):1119-1128.
132. + T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011, 63(6):1738-1747.
133. Wynn T.A. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011, 208(7):1339-1350.
134. Belperio J.A., Dy M., Burdick M.D., Xue Y.Y., Li K., Elias J.A., et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2002, 27(4):419-427.
135. Kolodsick J.E., Toews G.B., Jakubzick C., Hogaboam C., Moore T.A., McKenzie A., et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004, 172(7):4068-4076.
136. Nishimoto N., Terao K., Mima T., Nakahara H., Takagi N., Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008, 112(10):3959-3964.
137. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012, 52:199-219.
138. Matsushita T., Fujimoto M., Hasegawa M., Matsushita Y., Komura K., Ogawa F., et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007, 127(12):2772-2780.
139. Shima Y., Kuwahara Y., Murota H., Kitaba S., Kawai M., Hirano T., et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatol Oxf Engl 2010, 49(12):2408-2412.
140. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183(6):2593-2603.
141. Gutcher I., Donkor M.K., Ma Q., Rudensky A.Y., Flavell R.A., Li M.O. Autocrine transforming growth factor-beta1 promotes in vivo Th17 cell differentiationAutocrine transforming growth factor-β1 promotes in vivo Th17 cell differentiation. Immunity 2011, 34(3):396-408.
142. Yoshizaki A., Yanaba K., Iwata Y., Komura K., Ogawa A., Akiyama Y., et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 2010, 185(4):2502-2515.
143. Hill G.R., Olver S.D., Kuns R.D., Varelias A., Raffelt N.C., Don A.L., et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116(5):819-828.
144. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62(4):929-939.
145. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2(52). 52ra72.
146. Rankin A.L., Mumm J.B., Murphy E., Turner S., Yu N., McClanahan T.K., et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010, 184(3):1526-1535.
147. Manetti M., Ibba-Manneschi L., Liakouli V., Guiducci S., Milia A.F., Benelli G., et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010, 69(3):598-605.
148. Mozaffarian A., Brewer A.W., Trueblood E.S., Luzina I.G., Todd N.W., Atamas S.P., et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 2008, 181(10):7243-7253.
149. Shi-wen X., Kennedy L., Renzoni E.A., Bou-Gharios G., du Bois R.M., Black C.M., et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. Arthritis Rheum 2007, 56(12):4189-4194.
150. Shi-Wen X., Renzoni E.A., Kennedy L., Howat S., Chen Y., Pearson J.D., et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007, 26(8):625-632.
151. Seibold J.R., Denton C.P., Furst D.E., Guillevin L., Rubin L.J., Wells A., et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010, 62(7):2101-2108.
152. Kuhn A., Haust M., Ruland V., Weber R., Verde P., Felder G., et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: A prospective, open-label, non-comparative trial. Rheumatol Oxf Engl 2010, 49(7):1336-1345.
153. Giordano N., Puccetti L., Papakostas P., Di Pietra N., Bruni F., Pasqui A.L., et al. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with systemic sclerosis and pulmonary arterial hypertension: An open-label, observational, retrospective study. Int J Immunopathol Pharmacol 2010, 23(4):1185-1194.
154. Gu L., Tseng S., Horner R.M., Tam C., Loda M., Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000, 404(6776):407-411.
155. Gharaee-Kermani M., Denholm E.M., Phan S.H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271(30):17779-17784.
156. Distler O., Pap T., Kowal-Bielecka O., Meyringer R., Guiducci S., Landthaler M., et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001, 44(11):2665-2678.
157. Distler J.H., Jüngel A., Caretto D., Schulze-Horsel U., Kowal-Bielecka O., Gay R.E., et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006, 54(1):214-225.
158. Yamamoto T., Eckes B., Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: Differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001, 281(1):200-205.
159. Galindo M., Santiago B., Rivero M., Rullas J., Alcami J., Pablos J.L. Chemokine expression by systemic sclerosis fibroblasts: Abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 2001, 44(6):1382-1386.
160. Carulli M.T., Ong V.H., Ponticos M., Shiwen X., Abraham D.J., Black C.M., et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: Evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005, 52(12):3772-3782.
161. Schmidt K., Martinez-Gamboa L., Meier S., Witt C., Meisel C., Hanitsch L.G., et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009, 11(4):R111.
162. Fineschi S., Goffin L., Rezzonico R., Cozzi F., Dayer J.M., Meroni P.L., et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of Toll-like receptor 4. Arthritis Rheum 2008, 58(12):3913-3923.
163. Yamamoto T., Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003, 121(3):510-516.
164. Haringman J.J., Gerlag D.M., Smeets T.J., Baeten D., van den Bosch F., Bresnihan B., et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(8):2387-2392.
165. Yanaba K., Komura K., Kodera M., Matsushita T., Hasegawa M., Takehara K., et al. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: Association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann Rheum Dis 2006, 65(1):124-126.
166. Ong V.H., Evans L.A., Shiwen X., Fisher I.B., Rajkumar V., Abraham D.J., et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 2003, 48(7):1979-1991.
167. Hieshima K., Imai T., Baba M., Shoudai K., Ishizuka K., Nakagawa T., et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol 1997, 159(3):1140-1149.
168. Kodera M., Hasegawa M., Komura K., Yanaba K., Takehara K., Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: A sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005, 52(9):2889-2896.
169. Prasse A., Pechkovsky D.V., Toews G.B., Schäfer M., Eggeling S., Ludwig C., et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56(5):1685-1693.
170. Atamas S.P., Luzina I.G., Choi J., Tsymbalyuk N., Carbonetti N.H., Singh I.S., et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003, 29(6):743-749.
171. Luzina I.G., Papadimitriou J.C., Anderson R., Pochetuhen K., Atamas S.P. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte-dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum 2006, 54(8):2643-2655.
172. Luzina I.G., Tsymbalyuk N., Choi J., Hasday J.D., Atamas S.P. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006, 206(1):221-228.
173. Kodelja V., Müller C., Politz O., Hakij N., Orfanos C.E., Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998, 160(3):1411-1418.
174. Galli S.J., Borregaard N., Wynn T.A. Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nat Immunol 2011, 12(11):1035-1044.
175. Luzina I.G., Atamas S.P., Wise R., Wigley F.M., Xiao H.Q., White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002, 26(5):549-557.
176. Cipriani P., Franca Milia A., Liakouli V., Pacini A., Manetti M., Marrelli A., et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis Rheum 2006, 54(9):3022-3033.
177. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56(6):1994-2004.
178. Hayakawa I., Hasegawa M., Matsushita T., Yanaba K., Kodera M., Komura K., et al. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatol Oxf Engl 2005, 44(7):873-878.
179. Rabquer B.J., Tsou P.S., Hou Y., Thirunavukkarasu E., Haines G.K., Impens A.J., et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther 2011, 13(1):R18.
180. Hasegawa M., Sato S., Echigo T., Hamaguchi Y., Yasui M., Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005, 64(1):21-28.
181. Hasegawa M., Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci 2008, 13:3637-3647.
182. Abraham D., Lupoli S., McWhirter A., Plater-Zyberk C., Piela T.H., Korn J.H., et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991, 34:1164-1172.
183. Scharffetter K., Lankat-Buttgereit B., Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988, 18:9-17.
184. Matsushita Y., Hasegawa M., Matsushita T., Fujimoto M., Horikawa M., Fujita T., et al. Intercellular adhesion molecule-1 deficiency attenuates the development of skin fibrosis in tight-skin mice. J Immunol 2007, 179(1):698-707.
185. Rabquer B.J., Hou Y., Del Galdo F., Kenneth Haines G., Gerber M.L., Jimenez S.A., et al. The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1. Rheumatol Oxf Engl 2009, 48(7):734-740.
186. Hou Y., Rabquer B.J., Gerber M.L., Del Galdo F., Jimenez S.A., Haines G.K., et al. Junctional adhesion molecule-A is abnormally expressed in diffuse cutaneous systemic sclerosis skin and mediates myeloid cell adhesion. Ann Rheum Dis 2010, 69(1):249-254.
187. Luzina I.G., Todd N.W., Nacu N., Lockatell V., Choi J., Hummers L.K., et al. Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes. Arthritis Rheum 2009, 60(5):1530-1539.
188. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005, 52(9):2897-2905.
189. Horan G.S., Wood S., Ona V., Li D.J., Lukashev M.E., Weinreb P.H., et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008, 177(1):56-65.